Key result
The EINSTEIN CHOICE study is designed to determine whether two doses of rivaroxaban are superior to aspirin for the prevention of recurrent VTE in 2,850 patients.
Why the study?
Does rivaroxaban (10 mg or 20 mg daily) prevent symptomatic recurrent VTE compared to aspirin in patients with unprovoked VTE who completed 6-12 months of initial anticoagulant therapy?
RCT (n=2,850)
double-blind
randomised
Yes
Does rivaroxaban (10 mg or 20 mg daily) prevent symptomatic recurrent VTE compared to aspirin in patients with unprovoked VTE who completed 6-12 months of initial anticoagulant therapy?
The EINSTEIN CHOICE study protocol outlines a randomized trial to determine if rivaroxaban (10 mg or 20 mg) is superior to aspirin for extended VTE treatment.
Answers are grounded in this paper and cite their sources.
Tests rivaroxaban doses vs aspirin for extended VTE prevention; extends prior trials with this large RCT in unprovoked cases.
Patients with unprovoked venous thromboembolism (VTE) are at high risk for recurrence. Although rivaroxaban is effective for extended VTE treatment at a dose of 20 mg once daily, use of the 10 mg dose may further improve its benefit-to-risk ratio. Low-dose aspirin also reduces rates of recurrent VTE, but has not been compared with anticoagulant therapy. The EINSTEIN CHOICE study is a multicentre, randomised, double-blind, active-controlled, event-driven study comparing the efficacy and safety of two once daily doses of rivaroxaban (20 and 10 mg) with aspirin (100 mg daily) for the prevention of recurrent VTE in patients who completed 6-12 months of anticoagulant therapy for their index acute VTE event. All treatments will be given for 12 months. The primary efficacy objective is to determine whether both doses of rivaroxaban are superior to aspirin for the prevention of symptomatic recurrent VTE, while the principal safety outcome is the incidence of major bleeding. The trial is anticipated to enrol 2,850 patients from 230 sites in 31 countries over a period of 27 months. In conclusion, the EINSTEIN CHOICE study will provide new insights into the optimal antithrombotic strategy for extended VTE treatment by comparing two doses of rivaroxaban with aspirin (clinicaltrials.gov NCT02064439).
No takes yet. Share an insight, caveat, or question.
Bauersachs et al. (2015) conducted an RCT in Venous thromboembolism (VTE) (n=2,850). Rivaroxaban vs. Aspirin (100 mg daily) was evaluated on Symptomatic recurrent VTE. The EINSTEIN CHOICE study is designed to determine whether two doses of rivaroxaban are superior to aspirin for the prevention of recurrent VTE in 2,850 patients.
Synapse has enriched 10 related papers. Consider them for comparative context: